JRSM > Volume 101, Number 3 > Pp. 139-143

This Article Figures Only Full Text Full Text (PDF) Send a Quick Comment Alert me when this article is cited Alert me when Quick Comments are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sheikh, A. Articles by Fenty, J. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Trends in national incidence, lifetime prevalence and adrenaline prescribing for anaphylaxis in England

Aziz Sheikh¹ Julia Hippisley-Cox² John Newton³   Justin Fenty²

¹ Allergy and Respiratory Research Group, Division of Community Health Sciences: GP Section, University of Edinburgh
² Community Health Sciences, University of Nottingham
³ Epidemiology and Public Health, University of Manchester

Correspondence to: Aziz Sheikh aziz.sheikh{at}ed.ac.uk

Background Analysis of primary healthcare datasets offers the possibility to increase understanding of the epidemiology of acute uncommon conditions such as anaphylaxis, but these datasets remain under-exploited.

Aim To investigate recent trends in the recorded incidence, lifetime prevalence and prescribing of adrenaline for anaphylaxis in England.

Methods QRESEARCH is one of the world's largest national aggregated health databases containing the records of over nine million patients. We extracted data on all patients with a recorded diagnosis of anaphylaxis and calculated annual age-sex standardized incidence and lifetime period prevalence rates for each year from 2001–2005. We also analysed trends in adrenaline prescribing in those with a recorded diagnosis of anaphylaxis. National population figures were used to estimate numbers of people in England that have experienced anaphylaxis at some point in their lives.

Results The age-sex standardized incidence of anaphylaxis was 6.7 per 100,000 person-years in 2001 and increased by 19% to 7.9 in 2005. Lifetime age-sex standardized prevalence of a recorded diagnosis of anaphylaxis was 50.0 per 100,000 in 2001 and increased by 51% to 75.5 in 2005. Prescribing of adrenaline increased by 97% over this period. By the end of 2005 there were an estimated 37,800 people that had experienced anaphylaxis at some point in their lives.

Conclusions Recorded incidence, lifetime prevalence and prescribing of adrenaline for anaphylaxis all showed substantial increases in recent years. An estimated 1 in 1,333 of the English population have at some point in their lives experienced anaphylaxis.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. R Simpson, J. Newton, J. Hippisley-Cox, and A. Sheikh Trends in the epidemiology and prescribing of medication for eczema in England J R Soc Med, March 1, 2009; 102(3): 108 - 117. [Abstract] [Full Text] [PDF]

				C. R Simpson, J. Newton, J. Hippisley-Cox, and A. Sheikh Incidence and prevalence of multiple allergic disorders recorded in a national primary care database J R Soc Med, November 1, 2008; 101(11): 558 - 563. [Abstract] [Full Text] [PDF]

				N. Ghouri, J. Hippisley-Cox, J. Newton, and A. Sheikh Trends in the epidemiology and prescribing of medication for allergic rhinitis in England J R Soc Med, September 1, 2008; 101(9): 466 - 472. [Abstract] [Full Text] [PDF]